HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Prioritizes Growing Brands Over Adding More; Increasing Costs Drive Prices Higher

Executive Summary

Colgate is “not in a hurry” to make deals with valuations high for businesses it would target, says CEO Noel Wallace. Increasing commodity costs and rising inflation have the company prioritizing growth on existing businesses.

You may also be interested in...



Colgate Stays Course On Earnings Forecast Against Stormy Headwinds From Costs

Higher material and packaging costs in North America drove Colgate’s Q2 operating profit down 21%. Oral care sales were the bright spot in an otherwise difficult quarter in North America, where total sales declined 4% due to COVID-related demand in 2020 and competitive pressure.

Colgate Weathers US ‘Perfect Storm,' Grows 6% Worldwide In Q1

Colgate-Palmolive's North American business slipped 0.5% on category deceleration associated with stockpiling and costs from raw materials and inflation, the New York-based firm reported on 30 April. Premium innovations, advertising and price increases should improve the business in the back half of the year.

P&G Begins US Price Increases In Baby And Feminine Care, Could Expand To Health, Beauty

P&G plans up to double-digit price increases in US baby care, feminine care and adult incontinence and will analyze raw material costs and foreign exchange impacts in its other product categories for other pricing changes.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel